Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (1-10 of 242) with videos related to

Pageof 25
Sort By:
Oncology Research and Treatment|June 6, 2015
Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataGouji Toyokawa, Takashi Seto
Current Treatment Options in Oncology|October 16, 2015
The Role of Radiotherapy in the Treatment of Small-Cell Lung CancerKaname Nosaki, Takashi Seto
Clinical Lung Cancer|December 4, 2020
NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted TherapyNaoki Haratake, Takashi Seto
Clinical Lung Cancer|July 3, 2014
ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Gouji Toyokawa, Takashi Seto
Respiratory Investigation|December 3, 2014
Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significanceGouji Toyokawa, Takashi Seto
Expert Review of Anticancer Therapy|December 22, 2018
ALK testing methods: is there a winner or loser?Yuka Kozuma, Gouji Toyokawa, Takashi Seto
Cancer Metastasis Reviews|September 7, 2015
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, et al.
JTO Clinical and Research Reports|September 30, 2021
Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in <i>EGFR</i>-Mutated Lung CancerNaoki Haratake, Toshihiro Misumi, Takeharu Yamanaka, et al.
Clinical Lung Cancer|November 21, 2016
W'ALK' Into the Next StageGouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Are Anthracycline-Based Regimens Truly Indicated To Be the Standard Chemotherapy Regimen for Thymic Carcinoma?Fumihiko Hirai, Ryo Toyozawa, Kaname Nosaki, et al.
Pageof 25

Showing results (1-10 of 242) with videos related to

Sort By:
Pageof 25
Oncology Research and Treatment|June 6, 2015
Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataGouji Toyokawa, Takashi Seto
Current Treatment Options in Oncology|October 16, 2015
The Role of Radiotherapy in the Treatment of Small-Cell Lung CancerKaname Nosaki, Takashi Seto
Clinical Lung Cancer|December 4, 2020
NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted TherapyNaoki Haratake, Takashi Seto
Clinical Lung Cancer|July 3, 2014
ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Gouji Toyokawa, Takashi Seto
Respiratory Investigation|December 3, 2014
Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significanceGouji Toyokawa, Takashi Seto
Expert Review of Anticancer Therapy|December 22, 2018
ALK testing methods: is there a winner or loser?Yuka Kozuma, Gouji Toyokawa, Takashi Seto
Cancer Metastasis Reviews|September 7, 2015
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, et al.
JTO Clinical and Research Reports|September 30, 2021
Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in <i>EGFR</i>-Mutated Lung CancerNaoki Haratake, Toshihiro Misumi, Takeharu Yamanaka, et al.
Clinical Lung Cancer|November 21, 2016
W'ALK' Into the Next StageGouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Are Anthracycline-Based Regimens Truly Indicated To Be the Standard Chemotherapy Regimen for Thymic Carcinoma?Fumihiko Hirai, Ryo Toyozawa, Kaname Nosaki, et al.
Pageof 25